12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aflibercept ophthalmic solution regulatory update

Bayer submitted to Japan's Ministry of Health, Labor and Welfare (MHLW) a regulatory application for VEGF Trap-Eye aflibercept to treat myopic choroidal neovascularization (CNV). The product is approved as Eylea in Japan, the U.S.,...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >